Search Results - "Rimel, Bj"

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study by Liu, Joyce F, Dr, Barry, William T, PhD, Birrer, Michael, MD, Lee, Jung-Min, MD, Buckanovich, Ronald J, MD, Fleming, Gini F, Prof, Rimel, BJ, MD, Buss, Mary K, MD, Nattam, Sreenivasa, MD, Hurteau, Jean, MD, Luo, Weixiu, MS, Quy, Philippa, MA, Whalen, Christin, BSN, Obermayer, Lisa, BA, Lee, Hang, PhD, Winer, Eric P, Prof, Kohn, Elise C, MD, Ivy, S Percy, MD, Matulonis, Ursula A, MD

“…Summary Background Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1,…”
Get full text

50 Therapeutic opportunities in the master transcription factor circuitries of clear cell carcinomas by Kinne, Nolan J., Ochoa, Soledad, Scott, Marla, Abbasi, Forough, Yu, Pak Hin, Haro, Marcela, Rimel, BJ, Lawrenson, Kate

“…Transcription factors are emerging as targets for novel therapeutics for the treatment of malignancies. We sought to evaluate functions of PAX8 and HNF1B in…”
Get full text

26 Patterns of palliative care referral and inpatient to outpatient palliative care transition in gynecological cancer patients with a focus on primary language: a single institution retrospective study by Huang, Dandi, O'Connor, Reed, Moran, Katherine, Kim, Justin, Do, Anthony, Liang, Margaret, Rimel, BJ, Kim, Kenneth

“…To evaluate the patterns of inpatient (IP) vs outpatient (OP) initiation of palliative care (PC) with a focus on primary language and factors associated with…”
Get full text

Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial Cancers by DEWDNEY, Summer B, RIMEL, B. J, THAKER, Premal H, THOMPSON, Dominic M, SCHMIDT, Amy, HUETTNER, Phyllis, MUTCH, David G, FENG GAO, GOODFELLOW, Paul J

“…Effective treatments for advanced endometrial cancer are lacking. Novel therapies that target specific pathways hold promise for better treatment outcomes with…”
Get full text

NRG GY012: A randomized phase II study comparing single-agent olaparib, single agent cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent or metastatic endometrial cancer by Mackay, Helen, Rimel, Bj, Bender, David

“…Abstract only TPS5609 Background: The Cancer Genome Atlas and others identified genomic events suggesting that endometrial cancer (EC) should be susceptible to…”
Get full text

The duality of option-listing in cancer care by Tate, Alexandra, Rimel, B.J.

“…•Listing treatment choices, termed option-listing (OL) can facilitate SDM.•In early disease, we find OL can constrain patient choice via physician…”
Get full text

Implementing genetic risk assessment in a community free clinic by Marsh, Leah, Kamara, Daniella, Rimel, BJ

“…Abstract only…”
Get full text

Endocervical adenocarcinoma biomarkers for immunotherapy: Descriptive analysis by Cerda, Victoria, Karamzadeh, Nooshin, Scott, Marla, Kinne, Nolan, Mayer, Christopher, Taylor, Kristin, Li, Andrew John, Kim, Kenneth H., Medeiros, Fabiola, Balzer, Bonnie, Rimel, Bj

“…e17526 Background: Adenocarcinoma and adenosquamous carcinoma of the cervix are subtypes of HPV related cervical cancer. As virally mediated tumors, they have…”
Get full text

Surgical window-of-opportunity study of megestrol acetate compared with megestrol acetate and metformin for endometrial intraepithelial neoplasia by Xu, Yanfei, Saiz, Allison, Rimel, Bj, Corr, Bradley, Secord, Angeles Alvarez, Clark, Leslie Horn, Kocherginsky, Masha, Schering, Tia, Benante, Kelly A., Kalinichenko, Kiril, Sauter, Edward, Samimi, Goli, Dimond, Eileen, Khan, Seema Ahsan, Barber, Emma Longley

“…TPS5601 Background: Endometrial Intraepithelial Neoplasia (EIN) is a precursor lesion to endometrial carcinoma (EC), the most common gynecologic cancer among…”
Get full text

Comparison of risk-reducing surgery in women with BRCA and non-BRCA ovarian cancer susceptibility genes by Schwartz, Zachary Phillip, Zakhour, Mae, Li, Andrew John, Walsh, Christine S., Rimel, Bj, Alvarado, Monica, Lentz, Scott E, Cass, Ilana

“…Abstract only 1547 Background: Risk reducing gynecologic surgery (RRSO) is standard of care for women with BRCA mutations. The optimal management for women…”
Get full text

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012 by Mackay, Helen, Nixon, Andrew B., Enserro, Danielle, Bender, David, Rimel, BJ, Powell, Matthew A., Richardson, Debra L., Holman, Laura L., Alluri, Nitya, Mathews, Cara Amanda, Garg, Ruchi, Gill, Sarah, Matei, Daniela, Leath, Charles A., Backes, Floor Jenniskens, Fleury, Aimee, Swisher, Elizabeth M.

“…5525 Background: NRG GY012 is a randomized, 3-arm phase II study, comparing olaparib (O) and the combination of cediranib and olaparib (CO) to the reference…”
Get full text

Gynecologic oncology, gender and relevant leadership in academic medicine by Temkin, Sarah Madhu, Rubinsak, Lisa, Benoit, Michelle F., Chandavarkar, Uma, Hong, Linda, Berry, Laurel K, Heisler, Christine A, Rimel, BJ, McGuire, William P.

“…Abstract only e19056 Background: Within academic medicine, there has been increasing attention to diversity and inclusion. We sought to characterize…”
Get full text

Rethinking breast cancer surveillance in women with BRCA-associated ovarian cancer in the post-solo trial era by John, Catherine S., Amersi, Farin F., Fong, Abigail, Gillen, Jessica, Moore, Kathleen N., Walsh, Christine S., Li, Andrew John, Rimel, Bj, Cass, Ilana

“…Abstract only 5565 Background: Patients with BRCA mutations are at increased risk of developing both breast (BC) and epithelial ovarian cancer (EOC). Optimal…”
Get full text

25 Crowdfunding pages identify unmet needs among gynecologic cancer patients by O'Connor, Reed, Huang, Dandi, Rimel, BJ, Kim, Kenneth, Li, Andrew, Manuel, Michael R., Liang, Margaret

“…To describe the unmet needs disclosed by patients crowdfunding for gynecologic cancer care and to draw comparisons between patients with cervical, uterine, and…”
Get full text

Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer by Rimel, BJ, Dockery, Lauren, Randall, Leslie M, Moore, Kathleen

“…Homologous recombination deficiency is a critical biologic feature of ovarian cancer. This weakness in DNA damage repair relies on functional poly(ADP-ribose)…”
Get full text

Statin use and survival in elderly patients with endometrial cancer by Yoon, Lara S, Goodman, Marc T, Rimel, BJ, Jeon, Christie Y

“…Abstract Background Endometrial cancer is the most common gynecologic cancer in the United States. Statins have demonstrated anti-cancer effects in other tumor…”
Get full text

Recurrence and survival analysis of robotic versus traditional laparoscopic staging of endometrial cancer in a Medicare population by Cohen, Joshua Garrett, Rimel, BJ, Jeon, Christie Y

“…Abstract only…”
Get full text

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004) by Fuh, Katherine Cynthia, Herzog, Thomas J., Moore, Kathleen N., Myers, Tashanna K. N., Rimel, BJ, Liu, Joyce F., Secord, Angeles Alvarez, Hamilton, Erika P., Reid, Thomas J., Lewin, Sharyn Nan, Mullen, Mary M, Mills, Kathryn A., Anderson, Randy, Rangwala, Reshma A.

“…Abstract only TPS5605 Background: The AXL receptor and its activating ligand, GAS6, are important drivers of metastasis and therapeutic resistance in human…”
Get full text

Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS) by Gresham, Gillian, Hendifar, Andrew Eugene, Gong, Jun, Asher, Arash, Walsh, Christine S., Rimel, BJ, Posadas, Edwin M., Diniz, Marcio, Herring, Maurice, Woubeshet, Bethy, Baynes, Rachel, Figlin, Robert A., Spiegel, Brennan, Freedland, Stephen J.

“…Abstract only TPS6651 Background: Advanced cancer patients undergo dynamic changes in their functionality and physical activity over the course of their…”
Get full text

ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC) by Hardy-Bessard, Anne-Claire, Moore, Kathleen N., Mirza, Mansoor Raza, Asselain, Bernard, Redondo, Andres, Pfisterer, Jacobus, Pignata, Sandro, Provencher, Diane M., Cibula, David, Reyners, Anna K.L., Bodnar, Lubomir, Glasspool, Rosalind, Papadimitriou, Christos, Eitan, Rami, Han, Sileny N., Duska, Linda R., Rimel, BJ, Divya, Gupta, Chen, Jian, Pujade-Lauraine, Eric

“…Abstract only TPS6101 Background: Despite surgery and CT (paclitaxel + carboplatin ± bevacizumab [bev]), 5-year survival rates remain low for patients (pts)…”
Get full text